Opus Genetics, Inc. IRD
4.18 USD -0.02 (-0.48%)
Nov 10, 2026, 10:46 AM EST
4.04 Day range 4.27
1.70 52-week range 7.07
- YTD
- +107.96%
- 1 year
- +112.18%
News
zacks.com Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.12 per share a year ago.
benzinga.com Opus Genetics Q3 EPS $(0.46) Misses $(0.15) Estimate, Sales $1.137M Miss $1.959M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.15) by 206.67 percent. This is a 84 percent decrease over losses of…
globenewswire.com Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for…
globenewswire.com Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
globenewswire.com Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…
benzinga.com FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early…
benzinga.com Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.- benzinga.com Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical developmentNew…
benzinga.com Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13 Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.- benzinga.com Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20 Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
benzinga.com Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
benzinga.com Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold and silver prices climbed.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
benzinga.com Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful…- benzinga.com Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9 Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional…
benzinga.com RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9 RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.- benzinga.com Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by…
- benzinga.com Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12)…
- benzinga.com Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may…
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
benzinga.com Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in
benzinga.com Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to…- benzinga.com Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
- benzinga.com Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13 Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
- benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $11 price target.
- benzinga.com Opus Genetics Files Prospectus For Offering 2.679M Common Shares On Behalf Of Selling Shareholders https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm
- benzinga.com Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $16.
- benzinga.com Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.
- benzinga.com Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11 Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of…
- benzinga.com Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7 Oral PresentationRestoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5The oral presentation, delivered by Tomas S. Aleman, M.D., primary study investigator, reported…
- benzinga.com Opus Genetics' OPGx-LCA5 Program Accepted Into FDA's Rare Disease Evidence Principles Program Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with…
benzinga.com This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downgrades, on analyst ratings page.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session